|
| 37784256 | Cord blood transplantation for AML: Comparable LFS in patients with de novo versus secondary AML in CR1, an ALWP/EBMT study. | Br J Haematol | 2024 |
| 36376378 | Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO. | Leukemia | 2023 |
| 37654670 | Pooled allogeneic faecal microbiota MaaT013 for steroid-resistant gastrointestinal acute graft-versus-host disease: a single-arm, multicentre phase 2 trial. | EClinicalMedicine | 2023 |
| 37581981 | Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3-mutated AML: a phase 3b trial. | Blood Adv | 2023 |
| 37735558 | Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial. | Leukemia | 2023 |
| 37571998 | Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with RARA gene overexpression. | Leuk Lymphoma | 2023 |
| 37311468 | Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial. | Lancet | 2023 |
| 37245522 | CPX-351 in higher risk myelodysplastic syndrome and chronic myelomonocytic leukaemia: a multicentre, single-arm, phase 2 study. | Lancet Haematol | 2023 |
| 37206269 | Regions of homozygosity confer a worse prognostic impact in myelodysplastic syndrome with normal karyotype. | EJHaem | 2023 |
| 37166707 | CAR-T Cells and the Kidney: Insights from the WHO Safety Database. | BioDrugs | 2023 |
| 36477975 | Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML. | Blood Adv | 2023 |
| 36477770 | Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group. | Blood Adv | 2023 |
| 36891749 | Post-transplantation Burkitt lymphoma: a retrospective study of 55 patients. | Haematologica | 2023 |
| 36261707 | Combining blinatumomab and donor lymphocyte infusion in B-ALL patients relapsing after allogeneic hematopoietic cell transplantation: a study of the SFGM-TC. | Bone Marrow Transplant | 2023 |
| 36394159 | Real-life challenges using personalized prognostic scoring systems in acute myeloid leukemia. | Cancer Med | 2023 |
| 34632574 | Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients. | Br J Dermatol | 2022 |
| 35438802 | A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations. | Br J Haematol | 2022 |
| 35452143 | Red blood cell transfusion burden in myelodysplastic syndromes (MDS) with ring Sideroblasts (RS): A retrospective multicenter study by the Groupe Francophone des Myélodysplasies (GFM). | Transfusion | 2022 |
| 36570694 | Relative Mitochondrial Priming Predicts Survival in Older AML Patients Treated Intensively. | Hemasphere | 2022 |
| 36139679 | How I Treat <i>TP53</i>-Mutated Acute Myeloid Leukemia and Myelodysplastic Syndromes. | Cancers (Basel) | 2022 |
| 34983928 | Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. | Nat Commun | 2022 |
| 34975158 | Marrow ring sideroblasts are highly predictive for TP53 mutation in MDS with excess blasts. | Leukemia | 2022 |
| 34999727 | Allogeneic stem cell transplantation as a curative therapeutic approach for VEXAS syndrome: a case report. | Bone Marrow Transplant | 2022 |
| 35115668 | Defibrotide-treated patients with anicteric or icteric veno-occlusive disease/sinusoidal obstruction syndrome after hematopoietic cell transplantation: an EBMT study. | Bone Marrow Transplant | 2022 |
| 35267586 | Measurable Residual Disease in High-Risk Acute Myeloid Leukemia. | Cancers (Basel) | 2022 |
| 35263986 | High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALL. | Haematologica | 2022 |
| 34674982 | Prognostic of Core Binding Factor (CBF) Acute Myeloid Leukemia With Complex Karyotype. | Clin Lymphoma Myeloma Leuk | 2022 |
| 34615986 | Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AML. | Leukemia | 2022 |
| 33449813 | Eprenetapopt (APR-246) and Azacitidine in <i>TP53</i>-Mutant Myelodysplastic Syndromes. | J Clin Oncol | 2021 |
| 33600210 | Eprenetapopt Plus Azacitidine in <i>TP53</i>-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM). | J Clin Oncol | 2021 |
| 33741139 | [We must respect the anti-SARS-CoV-2 vaccine schedule without delay in cancer patients under treatment]. | Bull Cancer | 2021 |
| 33570629 | Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort. | Blood Adv | 2021 |
| 33596765 | Data from French named patient program of quizartinib in relapsed/refractory acute myeloid leukemia. | Leuk Lymphoma | 2021 |
| 35251769 | Reprogramming monocyte-derived macrophages through caspase inhibition. | Oncoimmunology | 2021 |
| 34410352 | Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy. | Blood | 2021 |
| 34576266 | Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia. | Int J Mol Sci | 2021 |
| 34070902 | FLT3 Tyrosine Kinase Inhibitors for the Treatment of Fit and Unfit Patients with FLT3-Mutated AML: A Systematic Review. | Int J Mol Sci | 2021 |
| 34099492 | Dual Covalent Inhibition of PKM and IMPDH Targets Metabolism in Cutaneous Metastatic Melanoma. | Cancer Res | 2021 |
| 34151423 | Eltrombopag for myelodysplastic syndromes or chronic myelomonocytic leukaemia with no excess blasts and thrombocytopenia: a French multicentre retrospective real-life study. | Br J Haematol | 2021 |
| 33339900 | Scoring system for clinically significant CMV infection in seropositive recipients following allogenic hematopoietic cell transplant: an SFGM-TC study. | Bone Marrow Transplant | 2021 |
| 33108024 | Splenectomy before allogeneic hematopoietic cell transplantation for myelofibrosis: A French nationwide study. | Am J Hematol | 2021 |
| 32394477 | Azacitidine in patients older than 80Â years with acute myeloid leukaemia or myelodysplastic syndromes: a report on 115 patients. | Br J Haematol | 2020 |
| 31990086 | Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment. | Eur J Haematol | 2020 |
| 31865004 | Alternative Effective and Safe Induction Regimens for Newly Diagnosed Acute Myeloid Leukemia in Patients With Cardiac Contraindication to Anthracyclines. | Clin Lymphoma Myeloma Leuk | 2020 |
| 32100599 | Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy. | Leuk Lymphoma | 2020 |
| 31914241 | Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. | N Engl J Med | 2020 |
| 33351128 | Optimizing selection of double cord blood units for transplantation of adult patients with malignant diseases. | Blood Adv | 2020 |
| 32665699 | Retraction Note: LAMP2 expression dictates azacytidine response and prognosis in MDS/AML. | Leukemia | 2020 |
| 32826232 | The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies. | Cancer Discov | 2020 |
| 32380535 | Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results. | Blood Adv | 2020 |